

Cabozantinib

for previously treated well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended cabozantinib for inclusion on the MOH List of Subsidised Drugs for previously treated well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours. The decision was based on the unfavourable cost effectiveness compared to existing treatment options.

Clinical indication, subsidy class and MediShield Life claims eligibility for cabozantinib are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class	Eligible for MediShield Life claims (implementation date)
Cabozantinib 20 mg, 40 mg and 60 mg tablets	Treatment of patients with locally advanced unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (NETs) or extra-pancreatic NETs who have progressed following at least one prior systemic therapy other than somatostatin analogues.	Not recommended for subsidy	Yes ¹ (1 Sep 2026)

¹ Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
 Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.